Ovarian Neoplasms Clinical Trials in Cleveland, Ohio

3 studies are recruiting for ovarian neoplasms in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

    This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with platinum-resistant cancer, meaning their disease progressed d…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Cleveland Clinic, Cleveland, Ohio
    Locations
    267 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07213804 on ClinicalTrials.gov

  2. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center, Cleveland, Ohio
    Locations
    158 in total
    Run by
    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT04389632 on ClinicalTrials.gov

  3. A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

    This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592,…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    GSK Investigational Site, Cleveland, Ohio
    Locations
    25 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT04641247 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.